目的 探讨胃苏颗粒联合瑞巴派特治疗活动期胃溃疡的临床疗效。方法 选择2016年6月-2017年5月在同济大学附属同济医院接受治疗的活动期胃溃疡患者98例，随机分为对照组和治疗组，每组各49例。对照组患者口服瑞巴派特片，0.1 g/次，3次/d。治疗组在对照组治疗基础上口服胃苏颗粒，餐前30 min口服，5 g/次，3次/d。两组均连续治疗6周。观察两组的中医证候疗效和内镜疗效，比较两组治疗前后临床症状评分和胃黏膜炎症积分的变化情况。随访3、6个月，比较两组的复发率。结果 治疗后，对照组和治疗组的中医证候总有效率分别为83.67%、97.96%，内镜疗效总有效率分别为85.71%、97.96%；两组比较差异有统计学意义（P<0.05）。治疗后，两组上腹痛、腹胀、反酸、嗳气、烧心症状评分、胃黏膜慢性炎症积分、活动性炎症积分均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组上腹痛、腹胀、反酸、嗳气、烧心症状评分、胃黏膜慢性炎症积分、活动性炎症积分显著低于对照组，两组比较差异有统计学意义（P<0.05）。随访3个月，对照组和治疗组的复发率分别为14.29%、4.08%，两组比较差异无统计学意义；随访6个月，对照组和治疗组的复发率分别为22.45%、6.12%，两组比较差异有统计学意义（P<0.05）。结论 胃苏颗粒联合瑞巴派特治疗活动期胃溃疡具有较好的临床疗效，可有效减轻临床症状，提高溃疡愈合质量，加快炎症消退，具有一定的临床推广应用价值。

objective To investigate the clinical effect of Weisu Granules combined with rebamipide in treatment of active gastric ulcer. Methods Patients (98 cases) with active gastric ulcer in Tongji Hospital Affiliated to Tongji University from June 2016 to May 2017 were randomly divided into control (49 cases) and treatment (49 cases) groups. Patients in the control group were po administered with Rebamipide Tablets, 0.1 g/time, three times daily. Patients in the treatment group were po administered with Weisu Granules 30 min before the meal on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the curative effect of TCM syndrome and endoscopic effect were evaluated, and the changes of clinical symptom scores and gastric mucosa inflammation integrals in two groups before and after treatment were compared. Results After treatment, the curative effect of TCM syndrome in the control and treatment groups were 83.67% and 97.96%, respectively, endoscopic effect were 85.71% and 97.96%, respectively, and there was difference between two groups (P < 0.05). After treatment, abdominal pain score, abdominal distension score, acid reflux score, belching score, heartburn score, gastric mucosa chronic inflammation integral, and active inflammatory integral significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, abdominal pain score, abdominal distension score, acid reflux score, belching score, heartburn score, gastric mucosa chronic inflammation integral, and active inflammatory integral in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). Follow-up 3 months, the recurrence rates in the control and treatment groups were 14.29% and 4.08%, and there was no statistically significant difference between two groups. Follow-up 6 months, the recurrence rates in the control and treatment groups were 22.45% and 6.12%, and there was difference between two groups (P < 0.05). Conclusion Weisu Granules combined with rebamipide has remarkable clinical effect in treatment of active gastric ulcer, and can effectively reduce clinical symptoms, improve the quality of ulcer healing, and accelerate the subtraction of inflammation, which has a certain clinical application value.